Market capitalization | $267.96m |
Enterprise Value | $39.63m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.55 |
P/S ratio (TTM) P/S ratio | 10.50 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | -21.66% |
Revenue (TTM) Revenue | $25.52m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
7 Analysts have issued a Foghorn Therapeutics Inc forecast:
7 Analysts have issued a Foghorn Therapeutics Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 26 26 |
22%
22%
|
|
Gross Profit | 22 22 |
9%
9%
|
|
EBITDA | -99 -99 |
7%
7%
|
EBIT (Operating Income) EBIT | -102 -102 |
11%
11%
|
Net Profit | -91 -91 |
12%
12%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Adrian Gottschalk |
Employees | 116 |
Founded | 2015 |
Website | www.foghorntx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.